Safety Assessment of 2’-Fucosyllactose (2’-FL) as a Novel Food for Use in Food and Food Supplements (RP1476) DOI Creative Commons

Food Standards Agency,

Food Standards Scotland

FSA research and evidence., Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 1, 2024

The Food Standards Agency (FSA) and Scotland (FSS) received an application from Kyowa Hakko Bio Company Ltd, Japan (“the applicant”) for the authorisation of 2’-fucosyllactose (2’-FL) as a novel food in March 2022. is intended to be used source human identical milk oligosaccharide, 2’-FL, manufactured by microbial fermentation using genetically modified strain Escherichia coli W, then refined yield purified powder. This new seeking use within following categories: dairy products analogues, bakery wares, table-top sweeteners, foods special groups, beverages, supplements. supplements are not if other with added 2’-FL or breast consumed same day. uses levels those that have already been authorised produced strains E. BL21 (DE3), K-12 DH1, Corynebacterium glutamicum ATCC 13032. However, this also supplement infants, which currently authorised. To support FSA FSS their evaluation application, Advisory Committee on Novel Foods Processes (ACNFP) were asked review safety dossier supplementary information provided applicant. views taken into account who concluded applicant had sufficient assure food, 2-FL, was safe under proposed conditions use. anticipated intake considered nutritionally disadvantageous. assessment represents opinion FSS.

Language: Английский

Human milk oligosaccharides: bridging the gap in intestinal microbiota between mothers and infants DOI Creative Commons
Wen Sun, Lin Tao, Chen Qian

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 6, 2025

Breast milk is an essential source of infant nutrition. It also a vital determinant the structure and function intestinal microbial community, it connects mother microbiota. Human oligosaccharides (HMOs) are critical component in breast milk. HMOs can reach baby's colon entirely from become fermentable substrate for some microorganisms. enhance mucosal barrier affect host through immune function, which has therapeutic effect on specific diseases, such as necrotizing enterocolitis. In addition, changes microbiota reflect maternal link between infants related to Through breastfeeding, jointly bacteria. Therefore, positively influence establishment balance ensure function. be used supplement alternative therapy diseases.

Language: Английский

Citations

1
Scientific and technical assistance report on the evaluation of human‐identical milk oligosaccharides (HiMOs) as novel foods DOI Open Access
Dominique Turck, Paolo Colombo, Estefanía Noriega Fernández

et al.

EFSA Supporting Publications, Journal Year: 2024, Volume and Issue: 21(9)

Published: Sept. 1, 2024

Abstract EFSA was asked by the European Commission to provide scientific and technical assistance on evaluation of human‐identical milk oligosaccharides (HiMOs) as novel foods (NFs). In recent years, number authorisations HiMOs NFs has markedly increased, which may lead situations multiple concurrent uses. Since safety assessment is based comparison with ‘natural’ intake human (HMOs), i.e. HMO from in exclusively breastfed infants, a scoping literature review outsourced update database mean concentrations single total HMOs milk, relevant intakes were thus updated. It noted that infants up 16 weeks age fed infant formula, when adding all assessed at their highest maximum use levels across production methods, resulting daily sum are within natural range. These also estimated (DietEx) for most exposed population groups (i.e., young children) considering those food categories contribution overall HiMO follow‐on formulae, ready‐to‐eat meals, yoghurt cow milk). The P95 unlikely be higher than intakes. However, any possible would not necessarily imply concern since such estimates represent an upper end average can concluded currently there no concerns authorised or combined Nonetheless, consideration increased interest NFs, simplified but realistic approach proposed case new extensions already HiMOs.

Language: Английский

Citations

2
Safety of 2′‐fucosyllactose (2’‐FL) produced by a derivative strain (Escherichia coli SGR5) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283 DOI Creative Commons
Dominique Turck, Torsten Bohn,

Jacqueline Castenmiller

et al.

EFSA Journal, Journal Year: 2023, Volume and Issue: 21(11)

Published: Nov. 1, 2023

Following a request from the European Commission, EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion 2'-fucosyllactose (2'-FL) as novel food (NF) pursuant Regulation (EU) 2015/2283. The NF is mainly composed of human-identical milk oligosaccharide (HiMO) 2'-FL, but it also contains d-lactose, l-fucose, fucosylgalactose, difucosyllactose, d-glucose d-galactose, small fraction other related saccharides. produced by fermentation genetically modified strain (

Language: Английский

Citations

5
Safety of lacto‐N‐fucopentaose I/2’‐fucosyllactose (LNFP‐I/2’‐FL) mixture as a novel food pursuant to Regulation (EU) 2015/2283 DOI Creative Commons
Dominique Turck, Torsten Bohn,

Jacqueline Castenmiller

et al.

EFSA Journal, Journal Year: 2023, Volume and Issue: 21(12)

Published: Dec. 1, 2023

Following a request from the European Commission, EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion lacto-N-fucopentaose I (LNFP-I)/2'-fucosyllactose (2'-FL) mixture as novel food (NF) pursuant Regulation (EU) 2015/2283. The NF is mainly composed of human-identical milk oligosaccharides (HiMO) LNFP-I 2'-FL, but it also contains d-lactose, lacto-N-tetraose, difucosyllactose, 3-fucosyllactose, fructose isomer, 2'-fucosyl-d-lactulose, l-fucose 2'-fucosyl-d-lactitol, small fraction other related saccharides. produced by fermentation genetically modified strain (Escherichia coli K-12 DH1 MDO MP2173b) E. (DSM 4235). information provided identity, manufacturing process, composition specifications does not raise safety concerns. applicant intends add in variety foods, including infant formula (IF) follow-on formula, foods for infants toddlers, special medical purposes supplements (FS). target population general population. anticipated daily intake use IF similar estimated natural mean highest breastfed infants. Overall, ingredient at maximum proposed levels unlikely exceed level body weight basis. basis expected be safe groups. 2'-FL generally rather low. FS intended if with added components or human (for young children) are consumed same day. concludes that NF, under conditions use.

Language: Английский

Citations

4
Safety Assessment of 2’-Fucosyllactose (2’-FL) as a Novel Food for Use in Food and Food Supplements (RP1476) DOI Creative Commons

Food Standards Agency,

Food Standards Scotland

FSA research and evidence., Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 1, 2024

The Food Standards Agency (FSA) and Scotland (FSS) received an application from Kyowa Hakko Bio Company Ltd, Japan (“the applicant”) for the authorisation of 2’-fucosyllactose (2’-FL) as a novel food in March 2022. is intended to be used source human identical milk oligosaccharide, 2’-FL, manufactured by microbial fermentation using genetically modified strain Escherichia coli W, then refined yield purified powder. This new seeking use within following categories: dairy products analogues, bakery wares, table-top sweeteners, foods special groups, beverages, supplements. supplements are not if other with added 2’-FL or breast consumed same day. uses levels those that have already been authorised produced strains E. BL21 (DE3), K-12 DH1, Corynebacterium glutamicum ATCC 13032. However, this also supplement infants, which currently authorised. To support FSA FSS their evaluation application, Advisory Committee on Novel Foods Processes (ACNFP) were asked review safety dossier supplementary information provided applicant. views taken into account who concluded applicant had sufficient assure food, 2-FL, was safe under proposed conditions use. anticipated intake considered nutritionally disadvantageous. assessment represents opinion FSS.

Language: Английский

Citations

0